[go: up one dir, main page]

MXPA05004971A - Pronostico para malignidad hematologica. - Google Patents

Pronostico para malignidad hematologica.

Info

Publication number
MXPA05004971A
MXPA05004971A MXPA05004971A MXPA05004971A MXPA05004971A MX PA05004971 A MXPA05004971 A MX PA05004971A MX PA05004971 A MXPA05004971 A MX PA05004971A MX PA05004971 A MXPA05004971 A MX PA05004971A MX PA05004971 A MXPA05004971 A MX PA05004971A
Authority
MX
Mexico
Prior art keywords
hematological malignancy
prognostic
modulation
genes
relapsed
Prior art date
Application number
MXPA05004971A
Other languages
English (en)
Inventor
Mitch Raponi
Original Assignee
Johnson & Jonhson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Jonhson filed Critical Johnson & Jonhson
Publication of MXPA05004971A publication Critical patent/MXPA05004971A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los metodos para tratar cancer, y preferiblemente malignidades hematologicas, en pacientes incluyen en analisis de los perfiles de expresion y/o marcadores moleculares de un paciente para determinar el estado y/o prognosis del paciente; la invencion tambien provee metodos para determinar el estado y/o prognosis del paciente; tambien provee metodos para analizar si un paciente sin recidiva o no refractorio responde de manera probable al tratamiento con inhibidores de la farnesil transferasa (FTIs) y, opcionalmente, otros terapeuticos; los metodos tambien son utiles para monitorear la terapia del paciente y para seleccionar un curso de terapia; los genes modulados en respuesta al tratamiento con FTI se proveen y se utilizan en la formulacion de los perfiles.
MXPA05004971A 2004-05-06 2005-05-06 Pronostico para malignidad hematologica. MXPA05004971A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56863504P 2004-05-06 2004-05-06

Publications (1)

Publication Number Publication Date
MXPA05004971A true MXPA05004971A (es) 2005-11-23

Family

ID=35262133

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05004971A MXPA05004971A (es) 2004-05-06 2005-05-06 Pronostico para malignidad hematologica.

Country Status (9)

Country Link
EP (1) EP1612281A3 (es)
JP (1) JP2005333987A (es)
KR (1) KR20060045950A (es)
CN (1) CN1704478A (es)
AR (1) AR048945A1 (es)
AU (1) AU2005201935B2 (es)
BR (1) BRPI0503418A (es)
CA (1) CA2504403A1 (es)
MX (1) MXPA05004971A (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070106027A (ko) * 2005-02-16 2007-10-31 와이어쓰 백혈병의 진단, 예후 및 치료법의 선택을 위한 방법 및시스템
WO2008054598A2 (en) * 2006-09-29 2008-05-08 Schering Corporation Panel of biomarkers for prediction of fti efficacy
WO2010073218A2 (en) * 2008-12-23 2010-07-01 Koninklijke Philips Electronics N.V. Methylation biomarkers for predicting relapse free survival
RU2400750C1 (ru) * 2009-03-16 2010-09-27 Федеральное Государственное учреждение "Кировский научно-исследовательский институт гематологии и переливания крови Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "КНИИГиПК Росмедтехнологий") Способ определения факторов прогноза тяжелых геморрагических осложнений у больных острым промиелоцитарным лейкозом при диагностике
KR101903547B1 (ko) * 2010-04-29 2018-10-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 게놈 모델에 대한 데이터 통합을 이용하는 경로 인지 알고리즘 （ｐａｒａｄｉｇｍ）
RU2478206C1 (ru) * 2012-02-06 2013-03-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования рецидивов у больных острым лейкозом
CN107941681B (zh) * 2013-04-19 2021-07-30 艾皮恩蒂斯有限公司 鉴定生物样品中定量细胞组成的方法
RU2550944C2 (ru) * 2013-08-08 2015-05-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования развития терминальной стадии у больных хроническим миелолейкозом
WO2015144841A1 (en) * 2014-03-26 2015-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml patients
AU2019371243A1 (en) * 2018-10-30 2021-05-27 Bruker Spatial Biology, Inc. Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies
CN112250750B (zh) * 2020-10-21 2022-08-30 青岛肿瘤研究院 与含酪氨酸磷酸化修饰肽具有亲和力的变体sh2结构域
CN115369150A (zh) * 2022-08-05 2022-11-22 浙江丰能医药科技有限公司 一种急性白血病诊断的生物标志物分析方法及其应用
CN120366457A (zh) * 2025-04-24 2025-07-25 镇江市第一人民医院 Hoxb3基因甲基化在制备急性髓系白血病预后产品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1470247A2 (en) * 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей

Also Published As

Publication number Publication date
KR20060045950A (ko) 2006-05-17
JP2005333987A (ja) 2005-12-08
EP1612281A2 (en) 2006-01-04
AU2005201935B2 (en) 2012-04-26
CN1704478A (zh) 2005-12-07
AU2005201935A1 (en) 2005-11-24
CA2504403A1 (en) 2005-11-06
EP1612281A3 (en) 2007-02-21
AR048945A1 (es) 2006-06-14
BRPI0503418A (pt) 2006-04-11

Similar Documents

Publication Publication Date Title
MXPA05004971A (es) Pronostico para malignidad hematologica.
Russo et al. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies
WO2007095644A3 (en) Reagents and methods for cancer prognosis and pathological staging
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
WO2006042237A3 (en) B7-h1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2006012646A3 (en) Amacr cancer markers
AU2004205878A8 (en) Gene expression markers for breast cancer prognosis
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
WO2009036427A3 (en) Prostate cancer biomarkers
WO2008030986A3 (en) Molecular diagnosis and classification of malignant melanoma
WO2007093657A3 (es) Método para el diagnóstico molecular de cáncer de próstata y kit para implementar el método
NZ597363A (en) Prognosis prediction for colorectal cancer
WO2010099161A8 (en) Micrornas in never-smokers and related materials and methods
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
EP2574679A3 (en) Methods for in vitro hepatocellular carninoma prognosis
WO2009019368A3 (fr) Procede de dosage de la liver fatty acid-binding protein, de l'ace et du ca19-9 pour le diagnostic in vitro du cancer colorectal
EP2518509A3 (en) Molecular prognosis and classification of malignant melanoma based upon markers selected from the list consisting of RGS1, NCOA3, SPP1, PHIP.
WO2009021054A3 (en) Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
PL2211180T3 (pl) Zastosowanie białka SATB2 jako markera do rozróżniania nowotworów jelita grubego od innych nowotworów
DE602004015626D1 (de) Bei brustkrebs
MX2010008008A (es) Estadificacion molecular en etapa ii y iii del cancer de colon y pronostico.
MX2013011431A (es) Metodos para predecir y mejorar la supervivencia de pacientes con cancer gastrico.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal